InsiderDXBi

Julphar

Growth Score40DXBi Rank138Heat Score100

Gulf Pharmaceutical Industries P.S.C.

UAE-based pharmaceutical manufacturer and the country's only insulin producer

Founded 1980Public (ADX-listed)Ras Al Khaimah, United Arab Emirates, Ras Al Khaimah1000+ employeesjulphar.net
Prospect profilepharmaceuticalsinsulinmanufacturingRas Al KhaimahADX-listedhealthcare
Visit Website

Media

Preview imagery published alongside each story, linking back to the original.

Overview

Julphar (Gulf Pharmaceutical Industries) is a UAE pharmaceutical manufacturer headquartered in Ras Al Khaimah, founded in 1980 and publicly listed on the Abu Dhabi Securities Exchange (ticker: JULPHAR). It manufactures and distributes general medicines, diabetes/insulin products (it is widely cited as the UAE's only insulin producer), and consumer healthcare products such as MEBO wound-care ointments, exporting to markets across the GCC, MENA, Africa and Asia. The company continues to report periodically as a listed entity, with H1 2026 results showing continued revenue growth and improved margins.
40

Growth Score

Steady

100

Heat Score

Trending up

Details

Operating Status
Active
Company Type
Public (ADX-listed)
Headquarters
Ras Al Khaimah, United Arab Emirates
Founded
1980
Company Size
1000+ employees
Revenue
$100M-$500M (H1 2026 revenue reported at AED 573.7 million / ~$156.2 million from continuing operations)

Stock listing

Abu Dhabi Securities Exchange (ADX): JULPHAR

Products & Services

General Medicines

Off-patent (generic-equivalent) medicines manufactured to originator quality standards, spanning cardiovascular, pain management, wound care and other therapeutic areas.

Insulin / Diabetes Solutions (recombinant DNA insulin)

Julphar is noted as one of the world's leading insulin manufacturers and the only MENA-based producer of local recombinant DNA insulin (branded historically as Julphar Diabetes Solutions).

MEBO / MEBO Scar

Moist Exposure Burn Ointment product line for treating burn injuries and scarring, and an associated scar-treatment product.

Vaccines

Vaccine manufacturing as part of Julphar's healthcare product portfolio.

Consumer Healthcare / Julphar Life

Consumer health division covering vitamin supplements and over-the-counter health products.

People

Technology

Tech stack

SAP S/4HANA (RISE with SAP)IBM Consulting Advantage (AI-powered delivery platform)Hybrid cloud infrastructure

Financials

Abu Dhabi Securities Exchange (ADX): JULPHAR

Stock

Funding rounds

Projects

Project LaunchAnnounced

Julphar Signs Lease Agreement with Modon Industrial City for Saudi Arabia Manufacturing Facility

Julphar formalized a lease agreement with Modon (3rd Industrial City) in Saudi Arabia to build an integrated pharmaceutical manufacturing facility, part of a planned investment of roughly SAR 300 million (about AED 293 million) over the coming years, intended partly as an export platform to international markets including the US.

$80M

Dec 22, 2025

PartnershipCompleted

Julphar and Global Investment House Form Planet Pharmacies Joint Venture

Julphar and Kuwait's Global Investment House announced the formation of Planet Pharmacies LLC, a pharmacy retail chain venture valued at approximately USD 245 million at formation, with Julphar contributing a distribution arm reported at around USD 150 million.

$245M

Aug 15, 2026

PartnershipAnnounced

Julphar Collaborates with IBM and SAP to Accelerate Enterprise Transformation

Julphar announced a strategic collaboration with IBM Consulting and SAP to modernize core operations via a RISE with SAP S/4HANA implementation, using IBM Consulting Advantage (AI-powered delivery), affecting finance, supply chain, manufacturing and HR functions across Julphar's 10 UAE manufacturing facilities. Quoted: CEO Basel Ziyadeh, IBM Consulting Managing Partner Lula Mohanty, and SAP MEA South Senior VP Sergio Maccotta.

Jul 20, 2026

Strategic InitiativeAnnounced

Gulf Pharmaceutical Industries (Julphar) Announces its Strategy 2030

Julphar announced its 'Strategy 2030' plan built on six pillars to drive sustainable growth, targeting over 100 new products.

Aug 14, 2026

Similar Companies

Official Channels

Where Julphar publishes directly. Each link is checked for the correct platform and profile format.

A tick means the link resolves to a valid company profile URL on that platform. It does not confirm the account is operated by Julphar — that requires a signal only the platform or the company can give, so DXBi does not claim it.

Press & Announcements

Every item links back to its original source. Announcements are only marked as coming from Julphar when the link resolves to the company's own domain.

Loading press coverage…

Signals & News

Insights

Reviews